American Journal of Clinical Dermatology, Год журнала: 2025, Номер unknown
Опубликована: Март 5, 2025
Язык: Английский
Процитировано
1
Australasian Journal of Dermatology, Год журнала: 2024, Номер 65(3), С. 260 - 265
Опубликована: Апрель 8, 2024
Abstract Background/Objectives The evaluation of the efficacy and safety new molecules for atopic dermatitis (AD) in real clinical practice is very important to obtain information that trials (EECC) lack. pattern AD head neck (H&N) continues be a challenge treatment today, despite molecules, real‐life data on use tralokinumab still missing. This first daily study patients with H&N pattern. objective evaluate short term (16 weeks) pattern, time. Methods A multicentre prospective observational was conducted, including moderate‐severe who started four hospitals Andalusia. Values severity quality life scales, as well patient‐reported outcomes (PROs), were collected at baseline Weeks 4 16. Safety events also recorded. Results Twelve included. An improvement observed all parameters evaluated 16 weeks respect baseline. No serious adverse Conclusions In practice, demonstrated an effective safe term.
Язык: Английский
Процитировано
6
Journal of Dermatological Treatment, Год журнала: 2023, Номер 34(1)
Опубликована: Май 29, 2023
Язык: Английский
Процитировано
16
Journal of Clinical Medicine, Год журнала: 2024, Номер 13(2), С. 553 - 553
Опубликована: Янв. 18, 2024
Background: Limited real-world data are available on upadacitinib drug survival in patients with atopic dermatitis (AD). Objectives: To investigate survival, and the reasons predictors of discontinuation AD patients. Methods: All consecutive aged 18–75 years, affected by moderate-to-severe AD, treated for more than 1 month at dermatological clinics were included during November 2020–August 2023. Upadacitinib was investigated through Kaplan–Meier analysis multivariable logistic regression analysis. Results: Overall, 325 adult (mean (SD) age, 38.6(15.6) years) had a 1-year 1.5-year 91.5% 80.2%, respectively. The main (25/325, 7.7%) adverse events (4.9%), including cutaneous or infectious diseases (1.5%), such as acne herpes zoster; blood test changes (1.2%), hypercholesterolemia, creatine phosphokinase liver enzyme elevation, lymphopenia; urinary respiratory infections (0.9%); deep venous thrombosis (0.3%); malignancies loss consciousness arthralgias followed ineffectiveness (0.6%). No specific characteristic significantly associated an increased risk discontinuation. Conclusions: Our findings show that effective after year continuous treatment but point to need clinical laboratory monitoring
Язык: Английский
Процитировано
5
Acta Dermato Venereologica, Год журнала: 2025, Номер 105, С. adv42275 - adv42275
Опубликована: Март 12, 2025
Tralokinumab is a monoclonal antibody selectively targeting IL-13, approved for moderate-to-severe atopic dermatitis (AD), which real-world data are scarce. This prospective, observational, multicentric study aimed to assess the long-term effectiveness and safety of tralokinumab in patients with AD setting. Primary outcomes included 50%, 75%, 90% improvement Eczema Area Severity Index score (EASI50, EASI75, EASI90, respectively) improvements Dermatology Life Quality (DLQI) at 1 year. A total 136 were enrolled study; 1-year follow-up available 111 patients. After year, 68.5% 33.3% achieved an EASI75 respectively. significantly higher percentage than without foot involvement EASI50 (p = 0.009) 0.022). Similarly, hand was associated response 0.005). Median DLQI decreased from 9.00 (interquartile range (IQR): 6.00, 13.75) 1.00 (IQR: 0.00, 4.00) after year treatment. Adverse events blepharitis (n 10), conjunctivitis 6), injection-site reactions 2). can be effective safe treatment AD. Involvement certain body areas, such as hands feet, might positively predict clinical tralokinumab.
Язык: Английский
Процитировано
0
Dermatology and Therapy, Год журнала: 2025, Номер unknown
Опубликована: Апрель 15, 2025
Язык: Английский
Процитировано
0
Journal of Asthma and Allergy, Год журнала: 2024, Номер Volume 17, С. 791 - 799
Опубликована: Авг. 1, 2024
Introduction:Even if mild forms of atopic dermatitis (AD) are usually well controlled with topical prescription drugs and emollients, the management severe disease may be challenging, especially in special populations (SPs).These patients include groups disadvantaged people (elderly, disabilities serious medical conditions) who excluded from clinical trials.As a consequence, most data about efficacy safety drug these derives post-marketing experiences.In this context, aim our study was to retrospectively investigate effectiveness tralokinumab AD SPs.Methods: A 24-weeks retrospective, dual-center performed enrolling diagnosis moderate-to-severe undergoing treatment at labelled dosage.Disease severity assessed using Eczema Area Severity Index (EASI), Pruritus-Numerical Rating Scale (P-NRS), Dermatology Life Quality (DLQI) score baseline after 4 weeks (W4), W16, W24.Adverse events (AEs) were monitored same timepoints.Statistical significance improvement (EASI, P-NRS, DLQI) week 4, 16, 24 as compared evaluated by Student's t-test, considering significant p-value <0.05.Results: Our 27 SPs showed EASI P-NRS since continuing improve up 24.Similarly, DLQI significantly decreases each timepoint baseline.Finally, no AEs reported during period.Of interest, cohort included oncologic patients, patient history infection, subjects affected neurological, psychiatric, pulmonary, and/or cardiovascular disease.Discussion: experience that is effective safe elderly comorbidities.
Язык: Английский
Процитировано
3
Journal of International Medical Research, Год журнала: 2024, Номер 52(11)
Опубликована: Ноя. 1, 2024
Atopic dermatitis (AD) is a common, chronic, and recurrent inflammatory skin condition that affects considerable portion of the population, particularly prevalent among children. The development AD influenced by environmental genetic factors, which cause epidermal barrier dysfunction, immune dysregulation, dysbiosis. In there excessive production cytokines. Among cytokines, interleukin (IL)-13 plays major role in pathogenesis AD. Searching for new more selective treatments moderate-to-severe cases important because effect on quality life. Tralokinumab lebrikizumab are IL-13 inhibitors have demonstrated safety efficacy as treatment options phase III trials. approved use Europe USA, while only Europe. Cendakimab, another inhibitor, has shown promising results II trials, providing safe effective outcomes. Eblasakimab, disrupts IL-4 signaling pathways, currently trials following well-tolerated administration I studies. This narrative review aims to outline current state knowledge regarding effectiveness these four biologic agents targeting signaling.
Язык: Английский
Процитировано
3
Expert Opinion on Biological Therapy, Год журнала: 2023, Номер 23(12), С. 1307 - 1315
Опубликована: Дек. 2, 2023
Background Tralokinumab is a human monoclonal antibody targeting interleukin-13 that approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing efficacy and safety tralokinumab in real-world setting are scarce.
Язык: Английский
Процитировано
5
Immunotherapy, Год журнала: 2023, Номер 15(16), С. 1341 - 1349
Опубликована: Авг. 29, 2023
Atopic dermatitis (AD) is an inflammatory skin disease that frequently occurs in adolescents. Although there are many treatment options, the challenge for clinicians finding effective long-term drug AD with a favorable safety profile. The purpose of this review to describe role tralokinumab, IL-13 inhibitor, treating adolescent AD. clinical efficacy and tralokinumab were established trials adults moderate-to-severe Based on results these preliminary conducted adolescents AD, effectively alleviates symptoms tolerable adverse effects. Extending use seems promising future.
Язык: Английский
Процитировано
4